We spoke to Dr Luigi Di Biase (Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA) on the current and new, emerging treatment strategies for the treatment of persistent atrial fibrillation, including the limitations of current pulmonary vein isolation, the concept of “beyond PVI” and clinical evidence supporting new ablation targets.
- What are the limitations of current pulmonary vein isolation (PVI) strategies in the treatment of persistent atrial fibrillation (AF)? (0:18)
- Could you give us an overview of the new and emerging ablation targets in persistent AF? (3:07)
- What do you feel complicates the concept of “beyond PVI”? (4:55)
- What clinical evidence supports approaches involving new ablation targets? (6:46)
Speaker disclosures: Dr Di Biase is a consultant for Biosense Webster, Stereoataxis and Rhythm management and has received speaker honoraria/travel support from Biosense Webster, St. Jude Medical (now Abbott), Boston Scientific, Medtronic, Biotronik, Pfizer and Bristol Meyers Squibb.
Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Dr Luigi Biase as a highlight of the AF Symposium, January 2021.
Share this Video
Related Videos In Interventional Cardiology
David Keane, AF Symposium 2021: Challenges in Catheter Ablation
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about the current challenges procedural duration and overall success in catheter ablation, and the most exciting innovations to aim to overcome these. Questions: What are the current challenges in catheter ablation in terms of procedural duration and overall success? (0.13) What are the […]
David Keane, AF Symposium 2021: Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy
We spoke to Professor David Keane (St Vincent’s University Hospital, Dublin, Ireland) about atrial fibrillation in patients with hypertrophic cardiomyopathy. Questions: What is the incidence of atrial fibrillation (AF) in people with hypertrophic cardiomyopathy (HCM)? (0.13) What is known about the efficacy and safety of catheter ablation of AF in patients with HCM compared to […]
Andrea Natale, AF Symposium 2021: Impact of Catheter Ablation on Quality of Life and Health Care Utilization
We spoke to Dr Andrea Natale (Texas Cardiac Arrhythmia Institute, Austin, TX, USA) about the most exciting recent innovations in catheter ablation technology. Questions: What is the impact of atrial fibrillation (AF) ablation on healthcare utilization and quality of life? (0.13) How should these data influence the timing of ablation strategies? (2.40) Speaker disclosures: Dr […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!